Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.


Main (gene editing) focus: Next-generation in vivo delivered gene-editing therapies

Company stage: Commercial

Diseases (gene editing): Genetic diseases of the liver, haemophilia, ophthalmology and autoimmune diseases

Genome editing tool: CRISPR-Cas9, Cas14 and Casɸ

Funding stage: Public (XETRA:BAYN.DE)

Location: Berlin, Germany



Gene editing partnerships: Mammoth Biosciences, Casebia Therapeutics

Bayer is a big pharma company with worldwide operations. The company is engaged in the gene-editing field by its joint venture firm, Casebia Therapeutics, which it launched together with CRISPR Therapeutics. The company also announced a collaboration with Mammoth Biosciences, where the two companies will utilise Mammoth's ultra-small Cas enzymes, Cas14 and Casɸ, for in vivo gene editing of multiple disease targets.



Company: Bayer
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine